Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines

Thyroid

Volumn 17, Issue 8, 2007, Pages 707-715

  Meireles, Ana Margarida ^a   Preto, Ana ^a   Rocha, Ana Sofia ^a   Rebocho, Ana Paula ^a   Máximo, Valdemar ^a,b   Pereira Castro, Isabel ^a   Moreira, Severina ^a   Feijão, Tália ^a   Botelho, Tiago ^a   Marques, Ricardo ^a   Trovisco, Vítor ^a,b   Cirnes, Luís ^a   Alves, Cíntia ^a   Velho, Sérgia ^a   Soares, Paula ^a,b   Sobrinho Simões, Manuel ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN PATCHED; PROTEIN RET; RAF PROTEIN; THYROID HORMONE RECEPTOR BETA;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CONTROLLED STUDY; CTNNB1 GENE; EXPERIMENTAL MODEL; GENE; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; ONCOGENE BRAF; ONCOGENE PTC; ONCOGENE RAS; ONCOGENE RET; PAX8 GENE; PRIORITY JOURNAL; PTC GENE; TG GENE; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; TP53 GENE; TPO GENE; TSHR GENE; TTF 1 GENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MICROSATELLITE REPEATS; THYROID NEOPLASMS;

EID: 36649017735     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0097     Document Type: Article

References (60)

1. Rosai J, Carcangiu ML, DeLellis RA 1992 Tumours of the Thyroid Gland. Armed Force Institute of Pathology, Washington, D.C.
2. Wynford-Thomas D 1997 Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm Res 47:145-157.
3. Buehring GC, Eby EA, Eby MJ 2004 Cell line cross-contamination: how aware are mammalian cell culturists of the problem and how to monitor it? In Vitro Cell Dev Biol Anim 40:211-215.
4. Sobel RE, Sadar MD 2005 Cell lines used in prostate cancer research: a compendium of old and new lines - part 2. J Urol 173:360-372.
5. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567.
6. Kopp P 2001 The TSH receptor and its role in thyroid disease. Cell Mol Life Sci 58:1301-1322.
7. Zannini M, Francis-Lang H, Plachov D, Di Lauro R 1992 Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol Cell Biol 12:4230-4241.
8. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, von zur Muhlen A, Vassart G, Dumont JE 1991 Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 82:R7-R12.
9. Carrasco N 1993 Iodide transport in the thyroid gland. Biochim Biophys Acta 1154:65-82.
10. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
11. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M 2003 E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580-587.
12. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580.
13. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
14. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G 2001 Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996.
15. Russell JP, Powell DJ, Cunnane M, Greco A, Portella G, Santoro M, Fusco A, Rothstein JL 2000 The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 19:5729-5735.
16. Rocha AS, Marques R, Bento I, Soares R, Magalhaes J, de Castro IV, Soares P 2007 Thyroid hormone receptor {beta} mutations in the "hot-spot region" are rare events in thyroid carcinomas. J Endocrinol 192:83-86.
17. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207.
18. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693.
19. Carson EB, McMahon M, Baylin SB, Nelkin BD 1995 Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res 55:2048-2052.
20. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N 2006 Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91:3662-3666.
21. Ham RG 1963 An improved nutrient solution for diploid Chinese hamster and human cell lines. Exp Cell Res 29:515-526.
22. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306.
23. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M 2004 BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4267-4271.
24. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D 1995 Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 10:49-59.
25. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371.
26. Christophe D 2004 The control of thyroid-specific gene expression: what exactly have we learned as yet? Mol Cell Endocrinol 223:1-4.
27. Damante G, Tell G, Di Lauro R 2001 A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acid Res Mol Biol 66:307-356.
28. Missero C, Cobellis G, De Felice M, Di Lauro R 1998 Molecular events involved in differentiation of thyroid follicular cells. Mol Cell Endocrinol 140:37-43.
29. Mittag J, Friedrichsen S, Heuer H, Polsfuss S, Visser TJ, Bauer K 2005 Athyroid Pax8-/- mice cannot be rescued by the inactivation of thyroid hormone receptor alpha1. Endocrinology 146:3179-3184.
30. Pasca di Magliano M, Di Lauro R, Zannini M 2000 Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97:13144-13149.
31. Basolo F, Giannini R, Toniolo A, Casalone R, Nikiforova M, Pacini F, Elisei R, Miccoli P, Berti P, Faviana P, Fiore L, Monaco C, Pierantoni GM, Fedele M, Nikiforov YE, Santoro M, Fusco A 2002 Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int J Cancer 97:608-614.
32. Russo D, Arturi F, Bulotta S, Pellizzari L, Filetti S, Manzini G, Damante G, Tell G 2001 Apel/Ref-I expression and cellular localization in human thyroid carcinoma cell lines. J Endocrinol Invest 24:RC10-RC12.
33. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627.
34. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16.
35. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sobrinho-Simoes M 2004 BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 444:572-576.
36. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X 2005 Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103:2261-2268.
37. Vandeput F, Perpete S, Coulonval K, Lamy F, Dumont JE 2003 Role of the different mitogen-activated protein kinase subfamilies in the stimulation of dog and human thyroid epithelial cell proliferation by cyclic adenosine 5′-monophosphate and growth factors. Endocrinology 144:1341-1349.
38. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP 2001 Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22:631-656.
39. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326.
40. Lazzereschi D, Mincione G, Coppa A, Ranieri A, Turco A, Baccheschi G, Pelicano S, Colletta G 1997 Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res 16:325-332.
41. Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB, Asa SL 1999 Oncogene profile of papillary thyroid carcinoma. Surgery 125:46-52.
42. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G 2003 ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226-3235.
43. Soares P, Cameselle-Teijeiro J, Sobrinho-Simoes M 1994 Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 24:205-210.
44. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760.
45. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
46. Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Roher HD, Williams ED, Wynford-Thomas D 1991 Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6:1693-1697.
47. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R 1993 Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381.
48. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simoes M 1998 Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 185:71-78.
49. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL 1999 Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811-1815.
50. Cerrato A, Fulciniti F, Avallone A, Benincasa G, Palombini L, Grieco M 1998 Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol 185:267-272.
51. Bohm J, Niskanen L, Kiraly K, Kellokoski J, Eskelinen M, Hollmen S, Alhava E, Kosma VM 2000 Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma. J Clin Endocrinol Metab 85:4806-4811.
52. Vermeulen SJ, Chen TR, Speleman F, Nollet F, Van Roy FM, Mareel MM 1998 Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient? Cancer Genet Cytogenet 107:76-79.
53. Rocha AS, De Wever O, Moreira S, Costa MJ, Vandekerckhove J, Mareel M, Soares P 2004 Mutated E-cadherin: genomic and functional characterization in thyroid cells from the KAT family. Thyroid 14:902-909.
54. Ishizaka Y, Itoh F, Tahira T, Ikeda I, Ogura T, Sugimura T, Nagao M 1989 Presence of aberrant transcripts of ret protooncogene in a human papillary thyroid carcinoma cell line. Jpn J Cancer Res 80:1149-1152.
55. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C 1994 Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73:2206-2212.
56. Antonini P, Linares G, Gaillard N, Venuat AM, Schlumberger M, Travagli JP, Caillou B, Berger R, Parmentier C 1993 Cytogenetic characterization of a new human papillary thyroid carcinoma permanent cell line (GLAG-66). Cancer Genet Cytogenet 67:117-122.
57. Savagner F, Chevrollier A, Loiseau D, Morgan C, Reynier P, Clark O, Stepien G, Malthiery Y 2001 Mitochondrial activity in XTC.UC1 cells derived from thyroid oncocytoma. Thyroid 11:327-333.
58. Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, Duh QY 1996 Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120:944-947.
59. Gustavsson B, Hermansson A, Andersson AC, Grimelius L, Bergh J, Westermark B, Heldin NE 1996 Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. Mol Cell Endocrinol 121:143-151.
60. Heldin NE, Cvejic D, Smeds S, Westermark B 1991 Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. Endocrinology 129:2187-2193.